VRDN Viridian Therapeutics, Inc.

NASDAQ
$31.44

Viridian Therapeutics, Inc. (VRDN) is expected to report earnings on February 3, 2027, before the market open. The consensus earnings estimate is a loss of $0.81 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +11.3% since its last earnings release on November 4, 2026.

Viridian Therapeutics Beat Consensus Estimates
Wednesday, November 4, 2026 · 7:01 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 3
Wednesday · 7:00 AM ET
Earnings Whisper
-
vs ($0.81)
Rev est $55.13M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $29.80

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Viridian Therapeutics, Inc.

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.